Osteoporose – was gilt beim älteren Nierenpatienten?

1 Osteoporosis Prevention, Diagnosis, and Therapy. NIH Consens Statement Online 2000 March 27–29, 2012

2 Prevention and Management of Osteoporosis. World Health Organization, 2012

3 Final Recommendation Statement – Osteoporosis to Prevent Fractures: Screening. In, U.S. Preventive Services Task Force 2018

4 Stone K.L. et al.: BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone MinerRes 2003; 18: 1947–1954

5 McCloskey E.: FRAX® Identifying people at high risk of fracture – WHO Fracture Risk Assessment Tool, a new clinical tool for informed treatment decisions. International Osteoporosis Foundation 2009

6 Harvey N.C. et al.: Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone 2015; 78: 216–224

7 Hans D. et al.: Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Mineral Res 2011; 26: 2762–2769

8 Conte G. et al.: Thresholds to define chronic kidney disease should not be age-dependent. Nephrol Dial Transplant 2014; 29: 770–774; discussion 780–772

9 Glassock R.J.: Thresholds to define chronic kidney disease should not be age dependent. Nephrol Dial Transplant 2014; 29: 774–779; discussion 779–782

10 Wetzels J.F.M. et al.: Age- and gender-specific reference values of estimated GFR in Caucasians: The Nijmegen Biomedical Study. Kidney International 2007; 72: 632–637

11 Moe S.M., Nickolas T.L.; Fractures in Patients with CKD: Time for Action. Clin J Am Soc Nephrol 2016; 11: 1929–1931

12 Yenchek R.H. et al.: Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol 2012; 7: 1130–1136

13 Whitlock R.H. et al.: The Fracture Risk Assessment Tool (FRAX(R)) predicts fracture risk in patients with chronic kidney disease. Kidney Int 2019; 95: 447–454

14 Naylor K.L. et al.: Trabecular Bone Score and Incident Fragility Fracture Risk in Adults with Reduced Kidney Function. Clin J Am Soc Nephrol 2016; 11: 2032–2040

15 Jamal S.A. et al.: Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 2007; 22: 503–508

16 Miller P.D. et al.: Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005; 20: 2105–2115

17 Ishani A. et al.: The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol 2008; 19: 1430–1438

18 Miller P.D. et al.: Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 2007; 18: 59–68

19 Jamal S.A. et al.: Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Mineral Res 2011; 26: 1829–1835

20 Block G.A. et al.: A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Mineral Res 2012; 27: 1471–1479